Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ALK Abello reports positive trends in first half of 2011

ALK Abello reports positive trends in first half of 2011

17th August 2011

ALK Abello has published its financial report for the first half of 2011, during which it was able to achieve a number of key business goals.

The company saw its revenue total for the six-month period grow by 20 percent year on year to 1.3 billion Danish kroner (148.5 million pounds), with North America and certain parts of Europe highlighted as key growth regions.

This builds on the success experienced by the firm in the first quarter of the year, during which it delivered sales and earnings that were in line with expectations.

Vaccine sales rose by eight percent in the half-year, while key clinical and regulatory milestones were achieved for the company's new ragweed allergy immunotherapy tablet, as well as the grass allergy tablet Grazax.

Moreover, a new licence agreement was reached with AllerQuest over the creation and marketing of a new diagnostic product for penicillin allergy.

As a result of these developments, ALK expects to achieve annual revenue of 2.3 billion Danish kroner for the year, as well as allergy vaccine sales growth of five percent.ADNFCR-8000103-ID-800702116-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.